All posts by: Michael Zand

About Michael Zand

Viruses May Be the Future of Boosting Immunotherapy in Brain Cancer – Curetoday.com

Continue reading

2018-02-07 NEWS

Curetoday.com

Viruses May Be the Future of Boosting Immunotherapy in Brain Cancer
Curetoday.com
In recent years, major advances have been made in the immunotherapy scape, as it has become instrumental in revolutionizing the way oncologists treat a variety of cancers. However, its success in patients with brain cancer has been extremely limited
Cancer injection eliminates tumors in miceFOX 4 News
Breakthrough cancer ‘vaccine’ may eventually eliminate tumors in rapid, inexpensive way, researchers findGrand Forks Herald
Human testing of new cancer vaccine underway after successful mice trialTechnoChops (press release) (blog)
Іnsіdеr Cаr Nеws
all 50 news articles »
Continue reading

2018-02-07 NEWS

Abeona’s gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%
Seeking Alpha
Abeona Therapeutics (ABEO +11.6%) is up on modestly higher volume in response to its announcement of encouraging data from the first MPS IIIB (Sanfilippo syndrome type B) patient treated with gene therapy candidate ABO-101. MPS IIIB
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical TrialGlobeNewswire (press release)
Why Abeona Therapeutics Jumped 14% on WednesdayMotley Fool
Maxim Group Assigns a Buy Rating on Abeona TherapeuticsAnalyst Ratings
BZ Weekly –StockNewsTimes
all 22 news articles »
Continue reading

2018-02-07 NEWS

Abeona’s gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%
Seeking Alpha
Abeona Therapeutics (ABEO +11.6%) is up on modestly higher volume in response to its announcement of encouraging data from the first MPS IIIB (Sanfilippo syndrome type B) patient treated with gene therapy candidate ABO-101. MPS IIIB
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical TrialGlobeNewswire (press release)
Why Abeona Therapeutics Jumped 14% on WednesdayMotley Fool
Maxim Group Assigns a Buy Rating on Abeona TherapeuticsAnalyst Ratings
BZ Weekly –StockNewsTimes
all 22 news articles »